Effect of pravastatin on renal function in patients with dyslipidemia and type 2 diabetes mellitus: A real-world observational study

Abstract Pravastatin can mitigate the progression of kidney disease; however, Asian data on its renal impact are lacking. This multicenter prospective observational study aimed to assess pravastatin’s effect on renal function in Korean patients with dyslipidemia and type 2 diabetes mellitus (T2DM) in real clinical practice. We enrolled 2,997 T2DM patients, who were followed up for 48 weeks post-pravastatin prescription. The effect of pravastatin on percent change in eGFR was assessed at weeks 12, 24, and 48 from baseline in patients ( n = 2,604) with available estimated glomerular filtration rate (eGFR) values. We noted a significant improvement in eGFR, with mean percent changes of + 2.53 ± 26.65, + 2.56 ± 27.69, and + 2.96 ± 28.82% at the respective time points (all p < 0.01). Positive eGFR outcomes were observed in subgroups with baseline eGFR < 90 mL/min/1.73m², age ≥ 65 years, T2DM duration > 5 years, baseline glycated hemoglobin (HbA1c) ≥ 7%, and prior statin therapy. Concurrently, the pravastatin group exhibited improvements in the 24th week in lipid levels, and glucose levels, including fasting blood glucose and HbA1c. Our findings emphasize pravastatin’s potential to improve eGFR in Korean patients with dyslipidemia and T2DM, thus aiding in the attenuation of kidney disease progression.